Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart drug delivers chemo directly to cancer cells in new trial

NCT ID NCT07439094

Recruiting now Disease control Sponsor: Chong Kun Dang Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducing harm to healthy cells. The trial will enroll 140 adults and first check safety and dosing, then measure how well the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CKD-703 (an antibody-drug conjugate that targets c-Met and delivers a chemotherapy drug directly to cancer cells)
What this could lead to
If successful, this could provide a new targeted treatment option for people with certain advanced cancers, especially non-small cell lung cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or may cause unexpected side effects. It is also only for people with specific genetic markers (c-Met), limiting who can benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Gabrail Cancer Center

    RECRUITING

    Ohio City, Ohio, 44718, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.